The main US indices ended Friday’s session weaker, as US economic growth cooled to the slowest pace in three years in the first quarter and geopolitical concerns reemerged.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) stock has moved in a downward direction this week, causing concern for some investors. Based on the recent close, the shares have dropped -7.14% over the past five trading days. Looking slightly further out, the stock is 12.35% year to date. With increased market volatility, stakeholders will likely be deciding whether or not now is a good time to cut losses or double down on the pullback.
Wall Street analysts are still seeing some upside to Adaptimmune Therapeutics plc (NASDAQ:ADAP) despite the recent move. Sell-side firms, on a consensus basis have a $13.14 price target on the name and a 2.00 recommendation, according to First Call. The recommendation is based on a 1 to 5 scale where 1 or 2 indicates a Buy recommendation, 3 a Hold and 4-5 a Sell.
In taking a look at technical levels,Adaptimmune Therapeutics plc (NASDAQ:ADAP) shares are trading -13.18% away from the 50 day simple moving average and -9.38% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -55.83% away from it’s 52- week high and 21.81% away from its 52 week low.
After the recent decrease, investors may also look to see if the stock has entered oversold territory and could possibly ripe for a reversal.
Traditionally a stock is considered to be oversold when the Relative Strength Index moves below 30. As of writing, Adaptimmune Therapeutics plc’s RSI stands at 26.14 . In looking at volatility levels, the shares saw weekly volatility of 4.57% and 4.49% over the past month.